Evidence map›Paper›PMID 36125775›Full record

ArticleChembiochem : a European journal of chemical biology2022

Tunable Toxicity of Bufadienolides is Regulated through a Configuration Inversion Catalyzed by a Short-Chain Dehydrogenase/Reductase.

Ge Ye, Weihuan Huang, Zeping Chen, Hao Zhong, Junhao Zhong, Xiaoxin Guo, Yuheng Huang, Shruthi Kandalai, Xiaozhuang Zhou, Nan Zhang and 3 more

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ge YeInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Weihuan HuangKey Laboratory of Regenerative Medicine, Ministry of Education, Jinan University, 601 West Huangpu Avenue, 510632, Guangzhou, P. R. China.
Zeping ChenInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Hao ZhongInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Junhao ZhongInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Xiaoxin GuoInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Yuheng HuangInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Shruthi KandalaiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, 420 W. 12th Ave, 43210, Columbus, Ohio, USA.
Xiaozhuang ZhouDepartment of Radiation Oncology, College of Medicine, The Ohio State University, 420 W. 12th Ave, 43210, Columbus, Ohio, USA.
Nan ZhangDepartment of Radiation Oncology, College of Medicine, The Ohio State University, 420 W. 12th Ave, 43210, Columbus, Ohio, USA.
Yang ZhouGuangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.
Qingfei ZhengDepartment of Radiation Oncology, College of Medicine, The Ohio State University, 420 W. 12th Ave, 43210, Columbus, Ohio, USA.ORCID 0000-0002-8397-3507
Haiyan TianInstitute of Traditional Chinese Medicine and Natural Products, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, 855 Xingye East Avenue, 510632, Guangzhou, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bufadienolides are toxic components widely found in amphibious toads that exhibit a wide range of biological activities. Guided by UPLC-QTOF-MS analysis, several 3-epi-bufadienolides with unique structures were isolated from the bile of the Asiatic toad, Bufo gargarizans. However, the enzymatic machinery of this epimerization in toads and its significance in chemical ecology remains poorly understood. Herein, we firstly compared the toxicities of two typical bufadienolides, bufalin (featuring a 14β-hydroxyl) and resibufogenin (containing a 14, 15-epoxy group), with their corresponding 3-epi isomers in a zebrafish model. The results of the toxicology assays showed that the ratio of maximum non-toxic concentrations of these two pairs of compounds are 256 and 96 times, respectively, thereby indicating that 3-hydroxyl epimerization leads to a significant decrease in toxicity. Aiming to investigate the biotransformation of 3-epi bufadienolides in toads, we applied liver lysate to transform bufalin and found that it could stereoselectively catalyze the conversion of bufalin into its 3α-hydroxyl epimer. Following this, we cloned and characterized a short-chain dehydrogenase/reductase, HSE-1, from the toad liver cDNA library and verified its 3(β→α)-hydroxysteroid epimerization activity. To the best of our knowledge, this is the first hydroxyl epimerase identified from amphibians that regulates the toxicity of animal-derived natural products.

Indexed as

BufanolidesShort Chain Dehydrogenase-ReductasesAnimalsBufo bufoCatalysisZebrafishBufanolidesShort Chain Dehydrogenase-Reductases3-epi bufadienolideshydroxysteroid epimerizationshort-chain dehydrogenase/reductasetoad livertoxicity

Identifiers

PMID36125775
PMCPMC9828183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.